Teva Achieves Investment-Grade Rating as Centene Receives Analyst Upgrade

Key Facts

In a move reflecting improved financial solvency within the healthcare sector, Teva Pharmaceutical Industries has achieved a significant milestone in its credit profile. According to analyst reports, Moody’s Ratings upgraded the company to an investment-grade rating of Baa3 with a stable outlook, citing the successful execution of its 'Pivot to Growth' strategy and debt reduction efforts. Simultaneously, Argus upgraded Centene Corp shares from hold to buy, driven by an improved margin outlook and the company's dominant position in the Medicaid market.

These upgrades come amid optimism regarding the companies' ability to restore profitability levels and improve cost efficiencies. Per market data, Teva's attainment of investment-grade status enhances its ability to lower borrowing costs and increases its eligibility for broader indices, while the $80 price target set for Centene reflects confidence in the firm's financial recovery.

At the close on August 10, 2026, the TEVA share price stood at $36.14, having reached a day high of $36.14 and a low of $35.00. Looking ahead, investors are monitoring the U.S. Initial Jobless Claims scheduled for August 6, 2026, which may provide further signals on macroeconomic stability and its impact on the healthcare services sector.